Holen Sie sich die Stockscreener-App
3.39
0.59%
-0.02
Handel nachbörslich:
3.39
Schlusskurs vom Vortag:
$3.41
Offen:
$3.37
24-Stunden-Volumen:
14,315
Relative Volume:
0.16
Marktkapitalisierung:
$37.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.25M
KGV:
-1.9045
EPS:
-1.78
Netto-Cashflow:
$-17.87M
1W Leistung:
+11.88%
1M Leistung:
-11.95%
6M Leistung:
-4.24%
1J Leistung:
-13.52%
1-Tages-Spanne:
$3.3091
$3.53
1-Wochen-Bereich:
$2.90
$3.56
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.39 | 38.14M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - ulpravda.ru
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in
Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда
Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize
What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber
Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда
Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World
Lantern Pharma Earnings Notes - Trefis
Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN
Lake Street Remains a Buy on Lantern Pharma (LTRN) - The Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal
Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser
Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser
Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news
Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia
Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus
Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com
Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa
Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq
Lantern Pharma Inc. (LTRN) Rises 9.5% in Pre-market: Amid Routine Trading - Stocks Telegraph
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Yahoo Finance
Can Jai Balaji Industries Limited Sustain EPS Growth Under Competitive PressureMorning Star Patterns & Zero-Cost Stock Research by Professionals - earlytimes.in
BIOS Capital Management LP Sells 131,757 Shares of Lantern Pharma Inc. $LTRN - Defense World
Is Lantern Pharma Inc. stock vulnerable to regulatory risksTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Is Lantern Pharma Inc. stock oversold or undervaluedJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
How Lantern Pharma Inc. stock reacts to global recession fearsMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - Sahm
Can Lantern Pharma Inc. stock deliver consistent earnings growth2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Is Lantern Pharma Inc. stock a buy before product launchesTrade Entry Summary & Daily Growth Stock Investment Tips - newser.com
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):